BR112020016929A8 - Métodos de uso para derivados de benzotriazol trissubstituídos - Google Patents
Métodos de uso para derivados de benzotriazol trissubstituídosInfo
- Publication number
- BR112020016929A8 BR112020016929A8 BR112020016929A BR112020016929A BR112020016929A8 BR 112020016929 A8 BR112020016929 A8 BR 112020016929A8 BR 112020016929 A BR112020016929 A BR 112020016929A BR 112020016929 A BR112020016929 A BR 112020016929A BR 112020016929 A8 BR112020016929 A8 BR 112020016929A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- benzotriazole derivatives
- trisubstituted benzotriazole
- trisubstituted
- variables
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2018018679 | 2018-02-20 | ||
| USPCT/US2018/018679 | 2018-02-20 | ||
| PCT/US2019/018472 WO2019164794A1 (en) | 2018-02-20 | 2019-02-19 | Methods of use for trisubstituted benzotriazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112020016929A2 BR112020016929A2 (pt) | 2020-12-15 |
| BR112020016929A8 true BR112020016929A8 (pt) | 2022-06-28 |
Family
ID=61692059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020016929A BR112020016929A8 (pt) | 2018-02-20 | 2019-02-19 | Métodos de uso para derivados de benzotriazol trissubstituídos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11717512B2 (https=) |
| EP (1) | EP3755324B1 (https=) |
| JP (2) | JP7434185B2 (https=) |
| KR (1) | KR102861339B1 (https=) |
| CN (1) | CN111757731B (https=) |
| AU (1) | AU2019223906B2 (https=) |
| BR (1) | BR112020016929A8 (https=) |
| CA (1) | CA3091792A1 (https=) |
| ES (1) | ES3038736T3 (https=) |
| MA (1) | MA51897A (https=) |
| MX (1) | MX2020008678A (https=) |
| TW (1) | TWI818954B (https=) |
| WO (1) | WO2019164794A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA48459B1 (fr) * | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| PE20212197A1 (es) * | 2018-12-21 | 2021-11-16 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
| CN111662872A (zh) * | 2020-05-06 | 2020-09-15 | 西南医科大学附属医院 | 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法 |
| CA3184024A1 (en) * | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) * | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996035419A1 (en) | 1995-05-10 | 1996-11-14 | Pfizer Inc. | Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| JP2003510352A (ja) | 1999-10-01 | 2003-03-18 | インスティチュート オブ モレキュラー アンド セル バイオロジー | ウイルス媒介性疾病の治療用化合物 |
| MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| PL382308A1 (pl) * | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
| ATE474833T1 (de) | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| JP2007015952A (ja) | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| DE102005049953A1 (de) | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP2066319B1 (en) | 2006-09-08 | 2012-02-01 | F. Hoffmann-La Roche AG | Benzotriazole kinase modulators |
| EP2387568A1 (en) | 2009-01-19 | 2011-11-23 | NeuroSearch A/S | Novel benzotriazole derivatives useful for the treatment of cns disorders |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| US9316632B2 (en) | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| WO2010115736A2 (en) | 2009-04-02 | 2010-10-14 | Merck Serono S.A. | Dihydroorotate dehydrogenase inhibitors |
| JP5967827B2 (ja) | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| CN103476770B (zh) | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| WO2013049112A1 (en) | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| CN103965133B (zh) | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| HRP20181908T1 (hr) | 2013-02-25 | 2019-01-11 | Aurigene Discovery Technologies Limited | Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PL3139914T3 (pl) | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| WO2017037022A1 (en) * | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| EP3397625A4 (en) | 2015-12-30 | 2019-12-25 | Agios Pharmaceuticals, Inc. | TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| US11311548B2 (en) | 2017-03-02 | 2022-04-26 | Aslan Pharmaceuticals Pte. Ltd. | Cancer therapy |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| MA48459B1 (fr) | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| KR102861339B1 (ko) * | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
| JP7608336B2 (ja) | 2018-11-30 | 2025-01-06 | フォンダッツィオーネ・セントロ・サン・ラッファエーレ | 中枢神経系原発リンパ腫の併用治療 |
| PE20212197A1 (es) | 2018-12-21 | 2021-11-16 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
| WO2021062157A1 (en) | 2019-09-27 | 2021-04-01 | The Rockefeller University | Compositions and methods for treating metastatic gastrointestinal cancer |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| CA3184024A1 (en) | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
-
2019
- 2019-02-19 KR KR1020207024137A patent/KR102861339B1/ko active Active
- 2019-02-19 AU AU2019223906A patent/AU2019223906B2/en active Active
- 2019-02-19 EP EP19707683.9A patent/EP3755324B1/en active Active
- 2019-02-19 BR BR112020016929A patent/BR112020016929A8/pt unknown
- 2019-02-19 MA MA051897A patent/MA51897A/fr unknown
- 2019-02-19 WO PCT/US2019/018472 patent/WO2019164794A1/en not_active Ceased
- 2019-02-19 US US16/971,199 patent/US11717512B2/en active Active
- 2019-02-19 CA CA3091792A patent/CA3091792A1/en active Pending
- 2019-02-19 TW TW108105398A patent/TWI818954B/zh active
- 2019-02-19 ES ES19707683T patent/ES3038736T3/es active Active
- 2019-02-19 MX MX2020008678A patent/MX2020008678A/es unknown
- 2019-02-19 CN CN201980014469.1A patent/CN111757731B/zh active Active
- 2019-02-19 JP JP2020566525A patent/JP7434185B2/ja active Active
-
2023
- 2023-05-29 JP JP2023087801A patent/JP2023109974A/ja active Pending
- 2023-06-09 US US18/207,887 patent/US12290508B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI818954B (zh) | 2023-10-21 |
| CN111757731B (zh) | 2024-06-25 |
| KR20200123137A (ko) | 2020-10-28 |
| KR102861339B1 (ko) | 2025-09-19 |
| MA51897A (fr) | 2020-12-30 |
| AU2019223906A1 (en) | 2020-09-10 |
| JP2023109974A (ja) | 2023-08-08 |
| US20240148697A1 (en) | 2024-05-09 |
| US11717512B2 (en) | 2023-08-08 |
| US20210113531A1 (en) | 2021-04-22 |
| AU2019223906B2 (en) | 2024-11-21 |
| JP2021514395A (ja) | 2021-06-10 |
| US12290508B2 (en) | 2025-05-06 |
| CN111757731A (zh) | 2020-10-09 |
| ES3038736T3 (en) | 2025-10-14 |
| EP3755324B1 (en) | 2025-07-30 |
| BR112020016929A2 (pt) | 2020-12-15 |
| CA3091792A1 (en) | 2019-08-29 |
| WO2019164794A1 (en) | 2019-08-29 |
| EP3755324A1 (en) | 2020-12-30 |
| MX2020008678A (es) | 2020-09-25 |
| TW201938543A (zh) | 2019-10-01 |
| EP3755324C0 (en) | 2025-07-30 |
| JP7434185B2 (ja) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020016929A8 (pt) | Métodos de uso para derivados de benzotriazol trissubstituídos | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| BR112018074621A2 (pt) | derivados de pirazolopirimidina como inibidores de quinase | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| CY1121334T1 (el) | Αναστολεας κινασης aurora a | |
| BR112019023290A2 (pt) | Tienopiridinas e benzotiofenos úteis como inibidores de irak4 | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| MX2019006830A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. | |
| EA202192151A1 (ru) | Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k | |
| AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
| BR112022000713A2 (pt) | Imidazopirimidinas como inibidores de eed e o uso das mesmas | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
| EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| BR112015020834A2 (pt) | novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1) | |
| CY1124851T1 (el) | Νεες ενωσεις |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: LES LABORATOIRES SERVIER SAS (FR) |
|
| B25D | Requested change of name of applicant approved |
Owner name: LES LABORATORIES SERVIER (FR) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: LES LABORATOIRES SERVIER SAS (FR) Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2686 DE 28/06/2022 POR TER SIDO INDEVIDA. |
|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: LES LABORATOIRES SERVIER SAS (FR) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO 870220031565, DE 12/04/2022, E NECESSARIO ANEXAR INSTRUMENTO DE PROCURACAO COM O NOME DO DEPOSITANTE CORRESPONDENTE A DOCUMENTACAO APRESENTADA. |
|
| B25D | Requested change of name of applicant approved |
Owner name: LES LABORATORIES SERVIER (FR) |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: LES LABORATOIRES SERVIER (FR) Free format text: RETIFICACAO DO DESPACHO (25.4) ? ALTERACAO DE NOME PUBLICADO NA RPI NO 2706, DE 16/11/2022, QUANTO AO ITEM (71) - DEPOSITANTE.ONDE SE LE: LES LABORATORIES SERVIERLEIA-SE: LES LABORATOIRES SERVIER |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |